ArticleScientific reports2025
Predictive value of myosteatosis and subcutaneous adipose tissue on the prognosis of ESCC patients undergoing chemoradiotherapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The relationship between CT-based body composition parameters and chemoradiotherapy outcomes in patients with esophageal squamous cell carcinoma (ESCC) is unclear. This study aimed to clarify the predictive value of myosteatosis and subcutaneous adipose tissue area (SATA) in ESCC patients undergoing chemoradiotherapy. The study cohort consisted of 255 ESCC patients undergoing chemoradiotherapy between January 2012 and December 2018. Body composition parameters, such as mean muscle density in Hounsfield units (HU) and adipose tissue area at the third lumbar vertebra (L3) level, were quantified on CT scans. Hazard ratios were estimated to establish the relationship between pretreatment skeletal muscle density (preSMD) and adipose tissue area with the overall survival (OS) rate. Optimal stratification was utilized to set threshold values. Kaplan-Meier plots and Cox proportional hazards models were developed to analyze survival distributions. Among 255 ESCC patients who received chemoradiotherapy, the median survival time was 24.3 months (95% CI 20.33-33.8). Multivariate analysis revealed that tumor length (HR = 1.547; 95% CI 1.115-2.145; P = 0.009), clinical stage (HR = 5.696; 95% CI 2.053-15.798; P < 0.001), and preSMD (HR = 1.528; 95% CI 1.079-2.169; P = 0.017) were independent indicators for OS. Additionally, SATA emerged as an independent predictor of preSMD (HR = 0.991; 95% CI 0.986-0.996; P = 0.038). A nomogram integrating preSMD, pretreatment subcutaneous adipose tissue area (preSATA), and independent prognostic factors effectively predicts the prognosis of ESCC patients, supplementing the TNM staging system. The study suggests that a prognostic model combining preSMD and preSATA effectively predicts the prognosis of ESCC patients undergoing chemoradiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.